Journal of gastroenterology and hepatology · 2026
Impact of Timing of Premedication on Mucosal Visibility During Endoscopy: A Randomized Controlled Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nabi Zaheer, Dasireddy Preethi Sudha, Sayyed Mahiboob, Reddy Praveen, Goud Rajesh, Rughwani Hardik, Singh Aniruddha Pratap, Inavolu Pradev, Reddy Palle Manohar, Basha Jahangeer, Gupta Rajesh, Tandan Manu, Reddy D Nageshwar
Аннотация
BACKGROUND: Adequate gastric mucosal visibility (GMV) is essential for high quality upper gastrointestinal (GI) endoscopy. Simethicone and N-acetylcysteine (NAC) are commonly used to improve mucosal visibility, but the optimal timing of administration remains uncertain.
OBJECTIVE: This double-blinded randomized controlled trial (RCT) evaluated the optimal interval between premedication (simethicone + NAC) and endoscopy for achieving adequate GMV.
DESIGN: In this RCT, adults undergoing elective upper GI endoscopy were randomized to four groups: placebo (Group 1), premedication to endoscopy interval of 10-20 (Group 2), 21-30 (Group 3), or > 30 min (Group 4). GMV was scored in four gastric regions (antrum, distal body, proximal body, fundus) on a 4-point scale (range 4-16). The primary outcome was adequate GMV (total score < 7). Secondary outcomes included median total GMV score, region-wise mucosal visibility scores, lesion detection rate, and predictors of adequate GMV.
RESULTS: A total of 1200 adults were randomized to four groups. Adequate GMV was significantly more frequent in Groups 3 (64.7%) and 4 (66.7%) than in placebo (2.7%) or Group 2 (25.0%). Subgroup analysis within Group 4 demonstrated a declining trend after 50 min. ROC analysis suggested an optimal cut-off of 25 min in predicting adequate GMV with area under the curve of 0.80. In region-wise analysis, mean visibility scores were lowest in antrum and distal body. There was no significant difference in the detection of gastric lesions across study groups (p = 0.913). No serious adverse events related to premedication were observed.
CONCLUSION: Premedication with simethicone and NAC significantly improves GMV. The improvement becomes optimal at 20-30 min after ingestion and is consistently maintained up to 50 min.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06581783.
OBJECTIVE: This double-blinded randomized controlled trial (RCT) evaluated the optimal interval between premedication (simethicone + NAC) and endoscopy for achieving adequate GMV.
DESIGN: In this RCT, adults undergoing elective upper GI endoscopy were randomized to four groups: placebo (Group 1), premedication to endoscopy interval of 10-20 (Group 2), 21-30 (Group 3), or > 30 min (Group 4). GMV was scored in four gastric regions (antrum, distal body, proximal body, fundus) on a 4-point scale (range 4-16). The primary outcome was adequate GMV (total score < 7). Secondary outcomes included median total GMV score, region-wise mucosal visibility scores, lesion detection rate, and predictors of adequate GMV.
RESULTS: A total of 1200 adults were randomized to four groups. Adequate GMV was significantly more frequent in Groups 3 (64.7%) and 4 (66.7%) than in placebo (2.7%) or Group 2 (25.0%). Subgroup analysis within Group 4 demonstrated a declining trend after 50 min. ROC analysis suggested an optimal cut-off of 25 min in predicting adequate GMV with area under the curve of 0.80. In region-wise analysis, mean visibility scores were lowest in antrum and distal body. There was no significant difference in the detection of gastric lesions across study groups (p = 0.913). No serious adverse events related to premedication were observed.
CONCLUSION: Premedication with simethicone and NAC significantly improves GMV. The improvement becomes optimal at 20-30 min after ingestion and is consistently maintained up to 50 min.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06581783.